Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000899243-17-012810
Filing Date
2017-05-11
Accepted
2017-05-11 15:55:28
Documents
3
Period of Report
2017-05-09

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 3279
2 EX-24.1 DOCUMENT attachment1.htm EX-24.1 4412
3 EX-24.2 DOCUMENT attachment2.htm EX-24.2 4424
  Complete submission text file 0000899243-17-012810.txt   14376
Mailing Address 19900 MACARTHUR BLVD. SUITE 550 IRVINE CA 92612
Business Address 19900 MACARTHUR BLVD. SUITE 550 IRVINE CA 92612 949-238-8090
Novus Therapeutics, Inc. (Issuer) CIK: 0001404281 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address 601 LEXINGTON AVENUE, 54TH FLOOR NEW YORK NY 10022-4629
Business Address 89 MEDINAT HAYEHUDIM STREET, 11TH FLOOR HERZLIYA L3 46766 212-739-6400
OrbiMed Israel GP Ltd. (Reporting) CIK: 0001569590 (see all company filings)

State of Incorp.: L3 | Fiscal Year End: 1231
Type: 3 | Act: 34 | File No.: 001-36620 | Film No.: 17834138

Mailing Address 601 LEXINGTON AVENUE, 54TH FLOOR NEW YORK NY 1022-4629
Business Address 89 MEDINAT HAYEHUDIM STREET, 11TH FLOOR HERZLIYA L3 46766 212-739-6400
OrbiMed Israel BioFund GP Limited Partnership (Reporting) CIK: 0001569821 (see all company filings)

State of Incorp.: L3 | Fiscal Year End: 1231
Type: 3 | Act: 34 | File No.: 001-36620 | Film No.: 17834137